Axogen, Inc. (AXGN) Spending and interest coverage
- R&D / revenue · 12 months: Value 14.35%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 14.99%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 14.35% | Research and development expense / revenue. Period ending 2026-06-30. $36.05M ÷ $251.17M × 100 ≈ 14.35% |
| Stock-based compensation / revenue · 12 months | 14.99% | Share-based compensation / revenue. Period ending 2026-06-30. $37.64M ÷ $251.17M × 100 ≈ 14.99% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 36.05M USD | Research and Development Expense |
| Revenue | 251.17M USD | |
| Stock-based compensation | 37.64M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -12.85M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $36.05M | $251.17M | $37.64M | $-12.85M | (m) | 14.35% | 14.99% | (m) | (m) |
| 2026-03-31 | $34.31M | $238.10M | $34.05M | $-9.02M | (m) | 14.41% | 14.30% | (m) | (m) |
| 2025-12-31 | $32.88M | $225.21M | $30.11M | $-7.85M | (m) | 14.60% | 13.37% | (m) | (m) |
| 2025-09-30 | $27.21M | $214.71M | $16.58M | $3.94M | (m) | 12.67% | 7.72% | (m) | (m) |
| 2025-06-30 | $26.64M | $203.27M | $16.16M | $1.71M | (m) | 13.11% | 7.95% | (m) | (m) |
| 2025-03-31 | $26.45M | $194.52M | $14.90M | $-388.00K | (m) | 13.60% | 7.66% | (m) | (m) |
| 2024-12-31 | $27.77M | $187.34M | $15.91M | $-3.29M | (m) | 14.82% | 8.49% | (m) | (m) |
| 2024-09-30 | $29.23M | $180.85M | $14.16M | $-8.50M | (m) | 16.16% | 7.83% | (m) | (m) |
| 2024-06-30 | $28.93M | $173.48M | $13.90M | $-12.21M | (m) | 16.68% | 8.01% | (m) | (m) |
| 2024-03-31 | $29.42M | $163.73M | $15.38M | $-18.68M | $5.14M | 17.97% | 9.40% | -3.63× | Reported |
| 2023-12-31 | $28.33M | $159.01M | $14.42M | $-21.46M | $2.83M | 17.82% | 9.07% | -7.57× | Reported |
| 2023-09-30 | $27.84M | $152.25M | $17.25M | $-23.88M | $952.00K | 18.29% | 11.33% | -25.08× | Reported |
| 2023-06-30 | $27.91M | $147.94M | $16.35M | $-24.71M | $185.00K | 18.86% | 11.05% | -133.56× | Reported |
| 2023-03-31 | $27.56M | $144.24M | $15.87M | $-25.73M | $286.00K | 19.11% | 11.00% | -89.96× | Reported |
| 2022-12-31 | $27.16M | $138.58M | $15.59M | $-29.71M | $624.00K | 19.60% | 11.25% | -47.61× | Reported |
| 2022-09-30 | $26.65M | $133.96M | $12.95M | $-29.45M | $593.00K | 19.89% | 9.66% | -49.67× | Reported |
| 2022-06-30 | $26.00M | $128.20M | $12.01M | $-31.29M | $949.00K | 20.28% | 9.37% | -32.97× | Reported |
| 2022-03-31 | $24.70M | $127.33M | $10.90M | $-30.52M | $1.27M | 19.40% | 8.56% | -24.10× | Reported |
| 2021-12-31 | $24.18M | $127.36M | $10.92M | $-25.42M | $1.36M | 18.98% | 8.57% | -18.74× | Reported |
| 2021-09-30 | $22.81M | $128.32M | $12.15M | $-25.44M | $2.02M | 17.77% | 9.47% | -12.58× | Reported |
| 2021-06-30 | $20.63M | $130.54M | $12.19M | $-19.79M | $2.00M | 15.81% | 9.34% | -9.89× | Reported |
| 2021-03-31 | $18.98M | $119.08M | $10.61M | $-20.89M | $1.47M | 15.94% | 8.91% | -14.24× | Reported |
| 2020-12-31 | $17.85M | $112.30M | $8.47M | $-23.18M | $1.05M | 15.89% | 7.54% | -21.99× | Reported |
| 2020-09-30 | $17.83M | $107.97M | $8.64M | $-25.23M | (m) | 16.51% | 8.01% | (m) | (m) |
| 2020-06-30 | $17.78M | $103.10M | $8.09M | $-30.29M | (m) | 17.24% | 7.85% | (m) | (m) |
| 2020-03-31 | $17.99M | $107.69M | $8.54M | $-29.71M | (m) | 16.70% | 7.93% | (m) | (m) |
| 2019-12-31 | $17.51M | $106.71M | $10.30M | $-31.41M | $40.00K | 16.41% | 9.66% | -785.15× | Reported |
| 2019-09-30 | $16.41M | $101.98M | $9.01M | $-29.84M | (m) | 16.09% | 8.83% | (m) | (m) |
| 2019-06-30 | $15.53M | $96.08M | $8.82M | $-28.57M | $22.00K | 16.17% | 9.19% | -1298.41× | Reported |
| 2019-03-31 | $13.85M | $89.96M | $8.19M | $-25.71M | $555.00K | 15.40% | 9.11% | -46.33× | Reported |
| 2018-12-31 | $11.77M | $83.94M | $7.61M | $-20.50M | $1.13M | 14.03% | 9.06% | -18.19× | Reported |
| 2018-09-30 | $9.94M | $77.48M | $7.10M | $-16.45M | (m) | 12.83% | 9.16% | (m) | (m) |
| 2018-06-30 | $8.43M | $70.86M | $5.81M | $-13.12M | $2.28M | 11.89% | 8.19% | -5.74× | Reported |
| 2018-03-31 | $7.35M | $65.45M | $4.49M | $-9.74M | $2.29M | 11.23% | 6.86% | -4.25× | Reported |
| 2017-12-31 | $6.70M | $60.43M | $3.61M | $-7.95M | $2.22M | 11.09% | 5.97% | -3.59× | Reported |
| 2017-09-30 | $5.91M | $54.86M | $2.84M | $-8.86M | $3.77M | 10.76% | 5.17% | -2.35× | Reported |
| 2017-06-30 | $5.23M | $50.02M | $2.21M | $-8.55M | $4.28M | 10.45% | 4.42% | -2.00× | Reported |
| 2017-03-31 | $4.64M | $45.24M | $2.06M | $-8.71M | $4.89M | 10.27% | 4.54% | -1.78× | Reported |
| 2016-12-31 | $4.21M | $41.11M | $1.39M | $-8.13M | $5.39M | 10.25% | 3.38% | -1.51× | Reported |
| 2016-09-30 | $3.93M | $37.51M | $1.33M | $-8.06M | $4.18M | 10.47% | 3.55% | -1.93× | Reported |
| 2016-06-30 | $3.74M | $34.46M | $1.37M | $-8.80M | $4.14M | 10.87% | 3.98% | -2.13× | Reported |
| 2016-03-31 | $3.54M | $30.49M | $1.13M | $-9.35M | $4.00M | 11.62% | 3.71% | -2.34× | Reported |
| 2015-12-31 | $3.24M | $27.33M | $1.32M | $-9.27M | $3.99M | 11.84% | 4.82% | -2.32× | Reported |
| 2015-09-30 | $3.33M | $24.32M | $1.29M | $-9.32M | $5.91M | 13.68% | 5.29% | -1.58× | Reported |
| 2015-06-30 | $3.07M | $20.83M | $1.18M | $-9.21M | $6.25M | 14.75% | 5.66% | -1.47× | Reported |
| 2015-03-31 | $2.89M | $18.63M | $1.07M | $-9.35M | $6.62M | 15.52% | 5.73% | -1.41× | Reported |
| 2014-12-31 | $3.03M | $16.82M | $956.45K | $-9.80M | $6.81M | 18.04% | 5.69% | -1.44× | Reported |
| 2014-09-30 | $2.68M | $15.01M | $838.91K | $-9.89M | $5.28M | 17.83% | 5.59% | -1.87× | Reported |
| 2014-06-30 | $2.59M | $13.29M | $753.56K | $-10.36M | $5.11M | 19.47% | 5.67% | -2.03× | Reported |
| 2014-03-31 | $2.53M | $11.94M | $669.52K | $-10.26M | $4.94M | 21.19% | 5.61% | -2.08× | Reported |
| 2013-12-31 | $2.13M | $10.95M | $671.89K | $-9.59M | $4.82M | 19.42% | 6.14% | -1.99× | Reported |
| 2013-09-30 | $1.87M | $10.01M | $551.05K | $-9.03M | $4.50M | 18.71% | 5.51% | -2.01× | Reported |
| 2013-06-30 | $1.67M | $9.03M | $558.49K | $-8.79M | $3.43M | 18.48% | 6.18% | -2.56× | Reported |
| 2013-03-31 | $1.54M | $8.18M | $597.13K | $-8.18M | $2.33M | 18.80% | 7.30% | -3.51× | Reported |
| 2012-12-31 | $1.43M | $7.69M | $495.08K | $-7.80M | $1.39M | 18.56% | 6.44% | -5.61× | Reported |
| 2012-09-30 | $1.31M | $7.01M | $631.25K | $-7.56M | $536.07K | 18.76% | 9.01% | -14.10× | Reported |
| 2012-06-30 | $1.15M | $6.17M | $519.11K | $-8.14M | $708.75K | 18.71% | 8.42% | -11.49× | Reported |
| 2012-03-31 | $887.89K | $5.38M | $377.90K | $-8.01M | $1.02M | 16.50% | 7.02% | -7.87× | Reported |
| 2011-12-31 | $697.36K | $4.85M | $250.04K | $-6.97M | $1.09M | 14.38% | 5.16% | -6.37× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $436.01K | $3.00M | $187.46K | $-4.48M | $814.99K | 14.51% | 6.24% | -5.50× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| TransMedics Group, Inc. (TMDX) | United States | $2.911B | 15.17 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| LivaNova PLC (LIVN) | $4.158B | 24.01 | |
| Integer Holdings Corp (ITGR) | United States | $4.289B | 25.17 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |